The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice
Marco Cerrano(Assistance Publique – Hôpitaux de Paris), Benedetto Bruno(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Gianfranco Pittari(Kettering University), Hesham Elsabah(National Center for Cancer Care and Research), Miriam Sánchez‐Escamilla(Cornell University), Danilo Faraci(Arcispedale Sant'Anna), Marta Coscia(University of Turin), Afraa Fadul(National Center for Cancer Care and Research), Enrico Maffini(Istituto di Ematologia di Bologna), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Luisa Giaccone(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Molly Maloy(Cornell University), Marco Ruella(Parker Institute for Cancer Immunotherapy), Candida Vitale(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)
Cited by 71
Related Papers
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation
|Blood|2014|880
Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease
|Biology of Blood and Marrow Transplantation|2015|762
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2020|739
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
|Journal of Clinical Investigation|2016|554